Fanconi syndrome and renal failure induced by tenofovir: A first case report

American Journal of Kidney Diseases

Volumn 40, Issue 6, 2002, Pages 1331-1333

  Verhelst, David ^a,b   Monge, Matthieu ^a,b   Meynard, Jean Luc ^a,b   Fouqueray, Bruno ^a,b   Mougenot, Béatrice ^a,b   Girard, Pierre Marie ^a,b   Ronco, Pierre ^a,b   Rossert, Jerome ^a,b  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Acquired immunodeficiency syndrome (AIDS); Fanconi syndrome; Nephrogenic diabetes insipidus; Nephrotoxicity; Renal failure; Tenofovir

Indexed keywords

ADEFOVIR; CIDOFOVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; TUBULAR DYSFUNCTION;

EID: 0036895460     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.36924     Document Type: Article

References (14)

1. Meier P, Dautheville-Guibal S, Ronco PM, Rossert J: Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 17:148-149, 2002
2. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD: Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 32:734-740, 2001
3. Deeks SG, Barditch-Crovo P, Lietman PS, et al: Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 42:2380-2384, 1998
4. Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46:716-723, 2002
5. Cihlar T, Ho ES, Lin DC, Mulato AS: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648, 2001
6. FDA Report: Background package for NDA 21-356: VIREAD (tenofovir disoproxil fumarate). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b1_03_FDA-tenofovir.pdf, 2001
7. Smith GC, Balfe JW, Kooh SW: Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 10:543-545, 1995
8. Bochet MV, Jacquiaud C, Valantin MA, Katlama C, Deray G: Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 105:457, 1998
9. Chugh S, Bird R, Alexander EA: Ritonavir and renal failure. N Engl J Med 336:138, 1997
10. Deray G, Bochet M, Katlama C, Bricaire F: [Nephrotoxicity of ritonavir]. Presse Med 27:1801-1803, 1998
11. Duong M, Sgro C, Grappin M, Biron F, Boibieux A: Renal failure after treatment with ritonavir. Lancet 348:693, 1996
12. Crowther MA, Callaghan W, Hodsman AB, Mackie ID: Dideoxyinosine-associated nephrotoxicity. AIDS 7:131-132, 1993
13. Kakuda TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708, 2000
14. Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T: Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 350:413-414, 1997